论文部分内容阅读
目的探讨左乙拉西坦联合卡马西平和托吡酯治疗难治性癫痫合并糖尿病的临床治疗效果。方法选取在我院住院治疗的难治性癫痫合并糖尿病患者80例,随机分为治疗组与对照组,分别给予不同的治疗措施,对两组患者的临床治疗效果进行对比分析。结果治疗组患者的临床疗效明显高于对照组,两组之间差异有统计学意义(P<0.05)。两组患者在治疗前的发作次数差异无统计学意义(P>0.05),治疗后治疗组患者的发作次数明显低于对照组,两组之间差异有统计学意义(P<0.05)。对照组患者中有6例患者出现不良反应,治疗组患者中5例患者出现不良反应,两组之间差异无统计学意义(P>0.05)。结论左乙拉西坦联合卡马西平和托吡酯治疗难治性癫痫合并糖尿病的临床治疗效果较好,能够有效降低癫痫发作的次数,具有较高的安全性,值得在临床治疗中应用。
Objective To investigate the clinical efficacy of levetiracetam in combination with carbamazepine and topiramate in the treatment of refractory epilepsy with diabetes. Methods Eighty patients with refractory epilepsy and diabetes mellitus who were hospitalized in our hospital were randomly divided into treatment group and control group, respectively. Different treatment measures were given to them, and the clinical effects were compared between the two groups. Results The clinical efficacy of the treatment group was significantly higher than that of the control group, the difference between the two groups was statistically significant (P <0.05). There was no significant difference in the number of seizures between the two groups before treatment (P> 0.05). The number of seizures in the treatment group was significantly lower than that in the control group after treatment, with significant difference between the two groups (P <0.05). In the control group, 6 patients showed adverse reactions, and 5 patients in the treatment group had adverse reactions. There was no significant difference between the two groups (P> 0.05). Conclusion Levetiracetam combined with carbamazepine and topiramate for the treatment of refractory epilepsy combined with diabetes better clinical treatment, can effectively reduce the number of seizures, with high safety, worthy of clinical application.